Stock of the Day

November 8, 2022

DexCom (DXCM)

$86.84
-$0.87 (-1.0%)
Market Cap: $32.83B

About DexCom

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

DexCom Bull Case

Here are some ways that investors could benefit from investing in DexCom, Inc.:

  • DexCom, Inc. recently demonstrated strong financial performance by beating analyst expectations in its most recent earnings report, posting earnings per share of $0.70 against a consensus estimate of $0.61 and generating revenue of $1.31 billion, which exceeded the projected $1.29 billion. This beat in both profitability and top-line growth, combined with a 13.1% year-over-year revenue increase, signals robust demand for its continuous glucose monitoring systems and validates the company's market position.
  • The stock has received significant recent support from Wall Street, with BTIG Research raising its price target to $96.00 and Barclays initiating coverage with an overweight rating, both indicating a bullish outlook. These recent analyst actions suggest that institutional investors see substantial upside potential, as the current stock price of $85.92 remains below the consensus target price of $92.22, implying further room for appreciation.
  • Institutional investors have shown strong conviction in the company's growth trajectory, with major funds such as UBS AM and Janus Henderson Group significantly increasing their holdings in recent quarters. This trend of institutional accumulation, where large asset managers are adding to their positions, often reflects deep fundamental research and confidence in the company's long-term viability and market leadership in the diabetes care sector.
  • DexCom, Inc. maintains a healthy balance sheet with a current ratio of 1.73 and a quick ratio of 1.43, indicating that the company has sufficient liquid assets to cover its short-term liabilities. This financial stability provides a buffer against economic downturns and allows the company to continue investing in its product portfolio, such as the Dexcom G7 system, without facing immediate liquidity constraints.
  • The company is benefiting from a favorable regulatory and market environment for its latest products, including the Dexcom G7 and Dexcom ONE, which are designed to replace traditional finger-stick testing. As the standard of care for diabetes management shifts toward continuous monitoring, DexCom's established brand and technological lead position it to capture a larger share of the growing global diabetes market.

DexCom Bear Case

Investors should be bearish about investing in DexCom, Inc. for these reasons:

  • There is a notable trend of insider selling, with executives and directors such as Kevin Sayer and Sadie Stern selling significant numbers of shares in recent months. For instance, Kevin Sayer sold 26,756 shares in July and May, and Sadie Stern sold shares in September and August. While these sales may be part of pre-arranged trading plans, a high volume of insider selling can sometimes signal that company insiders believe the stock is overvalued or that they are diversifying their personal wealth.
  • The stock is trading at a premium valuation with a P/E ratio of 33.96, which is higher than the broader market average. This high multiple means that investors are paying a significant price for each dollar of earnings, leaving less margin for error if the company's growth slows or if it faces increased competition. A high P/E ratio can lead to sharper price corrections if earnings disappoint or if market sentiment shifts negatively.
  • DexCom, Inc. faces intense competitive pressure in the continuous glucose monitoring market, with new entrants and established competitors launching their own devices. The recent drop in stock price ahead of earnings, attributed to profit-taking and competition concerns, highlights the sensitivity of the stock to market sentiment and the threat of losing market share to rival technologies that may offer similar features at lower prices.
  • The company has a beta of 1.48, indicating that its stock is more volatile than the overall market. This higher beta means that DexCom's share price is likely to experience larger swings in both directions compared to the S&P 500, which can be risky for investors who prefer stability. During market downturns, a high-beta stock like DXCM may fall more sharply than the broader market, amplifying potential losses.
  • Some institutional investors have reduced their stakes in the company, with funds like Bell Asset Management Ltd cutting their holdings by 52.9% in the third quarter. While other institutions are buying, the fact that some large players are exiting their positions suggests that there is divergence in opinion about the company's future performance and valuation, which can create uncertainty and volatility in the stock price.
← Previous Stock of the DayNext Stock of the Day →

Recent News